pharmaphorum| News & views on pharma and biotech’s evolving future

R&D

Cancer patient in hospital bed speaking with doctor

Human behaviour in cancer screening trials: A variable that ...

Behavioural phenomena are particularly consequential in screening and prevention research in oncology.

News

Agios' chief medical officer, Sarah Gheuens

Agios mulls early FDA filing for sickle cell therapy

Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.

R&D

The trust gap: GLP-1s and the new information economy of obe...

R&D

Test tubes being prepared for flow cytometry

Overcoming 6 data management challenges in flow cytometry

Large-scale flow cytometry delivers critical biological insight by enabling multidimensional analysis of individual cells, making it fundamental to medical research.

News

FDA points to liver injury with Amgen's Tavneos

The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.

Featured Content

R&D

Human behaviour in cancer screening trials: A variable that ...

Behavioural phenomena are particularly consequential in screening and prevention research in oncology.

R&D

The trust gap: GLP-1s and the new information economy of obe...

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Digital

BIO-Europe Spring podcast with Kashif Sadiq

Creating what nature has not from AI and computational molec...

Kashif Sadiq, founder and CEO of DenovAI Biotech discusses harnessing the power of artificial intelligence and computational molecular biophysics.

Patients

Interview at LSX 2026 with Hans Schambye

LSX2026: On promise and patience, with Hans Schambye

At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.

Sales & Marketing

Sponsored

What HCPs Say Pharma Gets Wrong About Survey Research

Most market researchers already know the standard rules: keep surveys concise, write clear questions, and reduce unnecessary respondent burden.

Newsletters and Deep Dive
digital magazine

Latest News

News

Agios mulls early FDA filing for sickle cell therapy

Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.

News

FDA points to liver injury with Amgen's Tavneos

The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.

News

NHS to offer Wegovy to a million more people in England

The NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.

News

Novo hits back at rivals with cut-price Wegovy subscriptions

Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.

Views & Analysis

R&D

Human behaviour in cancer screening trials: A variable that ...

Behavioural phenomena are particularly consequential in screening and prevention research in oncology.

R&D

Overcoming 6 data management challenges in flow cytometry

Large-scale flow cytometry delivers critical biological insight by enabling multidimensional analysis of individual cells, making it fundamental to medical research.

Patients